For many inhibitors that have been evaluated in in vivo models, although not exclusively, histone H3 phosphorylation at S10 has been the biomarker of choice to demonstrate MPS1 inhibition in tumours (Colombo et al, 2010; Jemaa et al, 2013). The gene discussed is TTK; the disease is neoplasm.